Diabetes cell therapy - Diatranz Otsuka Limited

Drug Profile

Diabetes cell therapy - Diatranz Otsuka Limited

Alternative Names: DiabeCell®; Immunoprotected (alginate-encapsulated) porcine islets - Diatranz Otsuka Limited

Latest Information Update: 06 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Living Cell Technologies
  • Developer Diatranz Otsuka Limited; Living Cell Technologies; Otsuka Pharmaceutical Factory Inc
  • Class Antihyperglycaemics; Cell therapies
  • Mechanism of Action Pancreatic beta cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Type 1 diabetes mellitus

Most Recent Events

  • 05 Oct 2017 Discontinued - Registered for Type-1 diabetes mellitus in Russia (Intraperitoneal) before October 2017, because no recent reports on development were identified and Diatranz Otsuka Limited is focussing its efforts on development in USA
  • 05 Oct 2017 Diatranz Otsuka Limited plans a phase II/III trial for Type 1 diabetes mellitus in USA (Diatranz Otsuka Limited website, October 2017)
  • 25 Mar 2015 No recent reports of development identified - Registered for Type-1 diabetes mellitus in Russia (Intraperitoneal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top